Barings’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-6,584
| Closed | -$507K | – | 212 |
|
|
2022
Q2 | $507K | Buy |
6,584
+1,022
| +18% | +$77.8K | 0.02% | 202 |
|
|
2022
Q1 | $407K | Hold |
5,562
| – | – | 0.01% | 218 |
|
|
2021
Q4 | $347K | Sell |
5,562
-774
| -12% | -$45.4K | 0.01% | 291 |
|
|
2021
Q3 | $375K | Sell |
6,336
-3,842
| -38% | -$253K | 0.01% | 266 |
|
|
2021
Q2 | $681K | Sell |
10,178
-1,316
| -11% | -$85.8K | 0.02% | 252 |
|
|
2021
Q1 | $726K | Sell |
11,494
-804
| -7% | -$50K | 0.02% | 264 |
|
|
2020
Q4 | $763K | Sell |
12,298
-131,078
| -91% | -$8.06M | 0.02% | 248 |
|
|
2020
Q3 | $8.64M | Sell |
143,376
-397
| -0.3% | -$23.9K | 0.2% | 86 |
|
|
2020
Q2 | $8.01M | Hold |
143,773
| – | – | 0.27% | 69 |
|
|
2020
Q1 | $8.01M | Buy |
143,773
+13,757
| +11% | +$841K | 0.27% | 69 |
|
|
2019
Q4 | $8.35M | Buy |
130,016
+32,738
| +34% | +$1.87M | 0.22% | 88 |
|
|
2019
Q3 | $4.93M | Buy |
97,278
+35
| +0% | +$1.65K | 0.11% | 166 |
|
|
2019
Q2 | $4.41M | Buy |
97,243
+26,132
| +37% | +$1.22M | 0.1% | 176 |
|
|
2019
Q1 | $3.39M | Buy |
71,111
+2,600
| +4% | +$130K | 0.08% | 192 |
|
|
2018
Q4 | $3.56M | Buy |
68,511
+14,000
| +26% | +$752K | 0.06% | 172 |
|
|
2018
Q3 | $3.38M | Sell |
54,511
-8,700
| -14% | -$516K | 0.05% | 238 |
|
|
2018
Q2 | $3.5M | Buy |
63,211
+16,532
| +35% | +$893K | 0.05% | 234 |
|
|
2018
Q1 | $2.95M | Hold |
46,679
| – | – | 0.04% | 282 |
|
|
2017
Q4 | $2.86M | Buy |
46,679
+6,800
| +17% | +$425K | 0.04% | 305 |
|
|
2017
Q3 | $2.54M | Hold |
39,879
| – | – | 0.05% | 264 |
|
|
2017
Q2 | $2.22M | Sell |
39,879
-40,879
| -51% | -$2.22M | 0.06% | 283 |
|
|
2017
Q1 | $4.39M | Buy |
80,758
+40,379
| +100% | +$2.21M | 0.05% | 355 |
|
|
2016
Q4 | $2.36M | Sell |
40,379
-37,000
| -48% | -$2.02M | 0.06% | 241 |
|
|
2016
Q3 | $4.17M | Buy |
77,379
+44,600
| +136% | +$2.86M | 0.11% | 114 |
|
|
2016
Q2 | $2.41M | Buy |
32,779
+1,200
| +4% | +$84.8K | 0.06% | 252 |
|
|
2016
Q1 | $2.02M | Sell |
31,579
-24,800
| -44% | -$1.56M | 0.05% | 293 |
|
|
2015
Q4 | $3.88M | Buy |
56,379
+17,000
| +43% | +$1.12M | 0.1% | 136 |
|
|
2015
Q3 | $2.33M | Sell |
39,379
-54,800
| -58% | -$3.48M | 0.06% | 247 |
|
|
2015
Q2 | $6.27M | Buy |
94,179
+40,000
| +74% | +$2.64M | 0.19% | 97 |
|
|
2015
Q1 | $3.5M | Sell |
54,179
-48,700
| -47% | -$3.05M | 0.08% | 194 |
|
|
2014
Q4 | $6.07M | Buy |
102,879
+25,100
| +32% | +$1.42M | 0.13% | 111 |
|
|
2014
Q3 | $3.98M | Buy |
77,779
+4,000
| +5% | +$200K | 0.09% | 166 |
|
|
2014
Q2 | $3.58M | Buy |
73,779
+50,100
| +212% | +$2.47M | 0.11% | 195 |
|
|
2014
Q1 | $1.23M | Sell |
23,679
-23,400
| -50% | -$1.25M | 0.04% | 404 |
|
|
2013
Q4 | $2.5M | Buy |
47,079
+18,700
| +66% | +$953K | 0.1% | 223 |
|
|
2013
Q3 | $1.31M | Sell |
28,379
-25,800
| -48% | -$1.13M | 0.06% | 369 |
|
|
2013
Q2 | $2.42M | Buy |
+54,179
| New | +$2.35M | 0.11% | 201 |
|
Other funds holding BMY
Barings's BMY Position: Q3 2022 in Review
Barings sold out of Bristol-Myers Squibb (BMY) in Q3 2022, closing a stake of 6,584 shares — an estimated $507K sold.
Barings first reported a position in BMY in Q2 2013 and held it in 37 quarters. The position peaked at $8.64M in Q3 2020. 2,469 funds tracked by Wall St. Rank hold BMY as of Q3 2022.
- Barings reported no remaining Bristol-Myers Squibb position as of Q3 2022 after selling out during the quarter.
- Barings sold 6,584 Bristol-Myers Squibb shares in Q3 2022, an estimated $507K.
- Barings first reported a position in Bristol-Myers Squibb in Q2 2013 and held it in 37 quarters.
- Barings's Bristol-Myers Squibb position peaked at $8.64M in Q3 2020.
- 2,469 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2022.
Based on Barings's 13F filing for Q3 2022, filed 14 Nov 2022.